Portfolio
Our biosimilars portfolio, consisting of hormones, proteins and monoclonal antibodies, spans multiple disease classes, for major indications in Oncology, Ophthalmology, Diabetes and Chronic Obesity. Our products target more than 800 million patients worldwide.
MTK01 | Insulin lispro
PK/PD Study
References Humalog® for Diabetes
MTK02 | Trastuzumab
PK/PD Study
References Herceptin® for Oncology
MTK03 | Ranibizumab
PK/PD Study
References Lucentis® for Ophthalmology
MTK04 | Asparaginase
PK/PD Study
References Crisantaspase® for Oncology
MTK05 | Pramlintide
PK/PD Study
References Symlin® for Diabetes & Chronic Obesity
MTK06 | Filgrastim
PK/PD Study
References Neupogen® for Oncology
MTK07 | Peg-filgrastim
PK/PD Study
References Neulasta® for Oncology
MTK09 | HSA
PK/PD Study
References Albuminar® for Multiple Indications
MTK08 | Adalimumab
Analytical
References Humira® for Immunology
MTK10 | Insulin Aspart
Early-stage
References Novolog® for Diabetes
MTK11 | Liraglutide
Early-stage
References Victoza® for Diabetes, Chronic Obesity
Partnerships
Our past partners span the spectrum, ranging from Fortune 100 and global enterprise companies, to pioneering startups, academic and research institutions, and regulatory agencies.
Get in touch with us today.